METHSUXIMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Methsuximide, and what generic alternatives are available?
Methsuximide is a drug marketed by Novitium Pharma and is included in one NDA.
The generic ingredient in METHSUXIMIDE is methsuximide. Two suppliers are listed for this compound. Additional details are available on the methsuximide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methsuximide
A generic version of METHSUXIMIDE was approved as methsuximide by NOVITIUM PHARMA on May 1st, 2023.
Summary for METHSUXIMIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Patent Applications: | 2,935 |
Formulation / Manufacturing: | see details |
DailyMed Link: | METHSUXIMIDE at DailyMed |
Pharmacology for METHSUXIMIDE
Drug Class | Anti-epileptic Agent |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for METHSUXIMIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novitium Pharma | METHSUXIMIDE | methsuximide | CAPSULE;ORAL | 217213-001 | May 1, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |